Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
The company might finally become an oncology player.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.